Iridex Appoints Patrick Mercer as Chief Executive Officer
Iridex (Nasdaq: IRIX), a leader in laser-based medical systems for glaucoma and retinal diseases, has announced significant leadership changes. Patrick Mercer, previously the company's Chief Operating Officer and President, has been appointed as the new Chief Executive Officer and President, effective October 1, 2024. This change comes as David Bruce, the former CEO, transitions out of the company.
Simultaneously, Scott Shuda has been named Executive Chairman of the board of directors, upgrading from his previous role as Chairman. The board believes these leadership changes could accelerate progress towards a potential transaction, as part of the strategic review process announced last year. Iridex continues to engage in discussions with multiple entities regarding potential transactions.
Mr. Mercer expressed his commitment to advancing Iridex's mission and highlighted the company's value as a global leader in ophthalmic laser treatment systems, featuring technologies like the Next Gen Pascal® with MicroPulse® for retina and MicroPulse Transscleral Laser Therapy for glaucoma.
Iridex (Nasdaq: IRIX), leader nei sistemi medici basati su laser per malattie della glaucoma e della retina, ha annunciato significativi cambiamenti nella leadership. Patrick Mercer, precedentemente Chief Operating Officer e Presidente dell'azienda, è stato nominato nuovo Chief Executive Officer e Presidente, con effetto dal 1 ottobre 2024. Questo cambiamento avviene mentre David Bruce, l'ex CEO, lascia l'azienda.
In contemporanea, Scott Shuda è stato nominato Presidente Esecutivo del consiglio di amministrazione, facendo un passo avanti rispetto al suo precedente ruolo di Presidente. Il consiglio crede che questi cambiamenti nella leadership possano accelerare i progressi verso una potenziale transazione, nell'ambito del processo di revisione strategica annunciato lo scorso anno. Iridex continua a essere impegnato in discussioni con più entità riguardo a potenziali transazioni.
Il signor Mercer ha espresso il suo impegno a far progredire la missione di Iridex e ha evidenziato il valore dell'azienda come leader globale nei sistemi di trattamento laser oftalmici, con tecnologie come il Next Gen Pascal® con MicroPulse® per la retina e la terapia laser transsclerale a MicroPulse per la glaucoma.
Iridex (Nasdaq: IRIX), líder en sistemas médicos basados en láser para enfermedades de glaucoma y retina, ha anunciado cambios significativos en su liderazgo. Patrick Mercer, anteriormente Director de Operaciones y Presidente de la compañía, ha sido nombrado nuevo Director Ejecutivo y Presidente, con efecto a partir del 1 de octubre de 2024. Este cambio se produce mientras David Bruce, el ex CEO, se transiciona fuera de la empresa.
Simultáneamente, Scott Shuda ha sido nombrado Presidente Ejecutivo de la junta directiva, ascendiendo desde su anterior papel como Presidente. La junta cree que estos cambios en el liderazgo podrían acelerar el progreso hacia una transacción potencial, como parte del proceso de revisión estratégica anunciado el año pasado. Iridex continúa participando en discusiones con múltiples entidades sobre transacciones potenciales.
El Sr. Mercer expresó su compromiso de avanzar en la misión de Iridex y destacó el valor de la compañía como líder global en sistemas de tratamiento láser oftálmico, con tecnologías como el Next Gen Pascal® con MicroPulse® para la retina y la terapia láser transescleral MicroPulse para el glaucoma.
Iridex (Nasdaq: IRIX)는 안과 질환 치료를 위한 레이저 기반 의료 시스템의 선두주자로서 중요한 리더십 변화를 발표했습니다. Patrick Mercer는 이전에 회사의 최고 운영 책임자(COO) 및 사장이었으며, 2024년 10월 1일부터 새로운 최고 경영 책임자(CEO) 및 사장으로 임명되었습니다. 이번 변화는 전 CEO인 David Bruce가 회사를 떠나는 가운데 이루어졌습니다.
동시에 Scott Shuda는 이사회의 집행 의장으로 임명되었으며, 이전의 의장 직에서 승진했습니다. 이사회는 이러한 리더십 변화가 작년 발표된 전략적 검토 프로세스의 일환으로 잠재적인 거래에 대한 진전을 가속화할 수 있다고 믿고 있습니다. Iridex는 다양한 단체와의 잠재적인 거래에 대해 계속 논의하고 있습니다.
머서는 Iridex의 사명을 향상시키려는 의지를 표명하며, 자사의 안과 레이저 치료 시스템에서의 글로벌 리더로서의 가치를 강조했습니다. 그런 기술들로는 망막을 위한 MicroPulse®가 탑재된 Next Gen Pascal®과 녹내장을 위한 MicroPulse 경막하 레이저 치료가 있습니다.
Iridex (Nasdaq: IRIX), leader dans les systèmes médicaux basés sur le laser pour les maladies du glaucome et de la rétine, a annoncé des changements significatifs au sein de sa direction. Patrick Mercer, précédemment directeur des opérations et président de la société, a été nommé nouveau directeur général et président, à compter du 1er octobre 2024. Ce changement intervient alors que David Bruce, l'ancien CEO, quitte l'entreprise.
Dans le même temps, Scott Shuda a été nommé président exécutif du conseil d'administration, passant de son rôle précédent de président. Le conseil estime que ces changements de leadership pourraient accélérer les progrès vers une transaction potentielle, dans le cadre du processus de révision stratégique annoncé l'année dernière. Iridex continue de mener des discussions avec plusieurs entités concernant des transactions potentielles.
M. Mercer a exprimé son engagement à faire avancer la mission d'Iridex et a souligné la valeur de l'entreprise en tant que leader mondial des systèmes de traitement au laser ophtalmique, avec des technologies telles que le Next Gen Pascal® avec MicroPulse® pour la rétine et la thérapie laser transsclérale MicroPulse pour le glaucome.
Iridex (Nasdaq: IRIX), ein führendes Unternehmen im Bereich laserbasierter medizinischer Systeme für Glaukom und Netzhauterkrankungen, hat erhebliche Veränderungen in der Unternehmensführung angekündigt. Patrick Mercer, zuvor Chief Operating Officer und Präsident des Unternehmens, wurde mit Wirkung zum 1. Oktober 2024 zum neuen Chief Executive Officer und Präsidenten ernannt. Diese Veränderung erfolgt im Zuge des Wechsels von David Bruce, dem ehemaligen CEO, der das Unternehmen verlässt.
Gleichzeitig wurde Scott Shuda zum Executive Chairman des Verwaltungsrats ernannt, nachdem er zuvor Vorsitzender war. Der Vorstand ist der Meinung, dass diese Veränderungen in der Unternehmensführung den Fortschritt in Richtung einer potentiellen Transaktion im Rahmen des im letzten Jahr angekündigten strategischen Überprüfungsprozesses beschleunigen könnten. Iridex führt weiterhin Gespräche mit mehreren Akteuren über potenzielle Transaktionen.
Herr Mercer drückte sein Engagement aus, die Mission von Iridex voranzutreiben, und hob den Wert des Unternehmens als globalen Marktführer im Bereich der ophthalmologischen Lasersysteme hervor, der Technologien wie das Next Gen Pascal® mit MicroPulse® für die Netzhaut und die transsklerale MicroPulse-Lasertherapie für Glaukom umfasst.
- Appointment of experienced internal candidate Patrick Mercer as new CEO
- Potential acceleration of strategic review process and transaction discussions
- Alignment between management and board of directors on unlocking company value
- Strong market position with industry-leading ophthalmic laser treatment technologies
- Departure of previous CEO David Bruce
- Ongoing strategic review process indicating potential company sale or restructuring
MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company’s Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company’s Chief Operating Officer and President. David Bruce, the Company’s prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer’s appointment, Scott Shuda was appointed Executive Chairman of the Company’s board of directors. Mr. Shuda had previously served as Chairman.
“Iridex’s board of directors believes a change in leadership at this time has potential to accelerate progress toward a transaction under the strategic review process that the Company announced and initiated last year. The Company has and continues to be engaged in discussions with multiple entities relating to potential transactions,” commented Scott Shuda, Executive Chairman of the Iridex board of directors.
Mr. Mercer added, “I am honored to assume the role of CEO at Iridex and lead our talented team as we continue to advance our mission of providing cutting-edge solutions for ophthalmic care. Iridex presents compelling value as a global leader in ophthalmic laser treatment systems, featuring industry-leading technology such as the Next Gen Pascal® with MicroPulse® for retina and MicroPulse Transscleral Laser Therapy for glaucoma. The Company’s management is aligned with the board of directors, and both are committed to completing the strategic review process and unlocking the value of these assets.”
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning pursuit of value-maximizing transactions and demand for and utilization of the Company's products. The Company can provide no assurance that it will complete any value-maximizing transactions on behalf of its stockholders. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
Who is the new CEO of Iridex (IRIX)?
What leadership changes occurred at Iridex (IRIX) in October 2024?
Why did Iridex (IRIX) change its CEO in October 2024?
What is Iridex 's (IRIX) main business focus?
